Interactive dashboards enable viewing and interacting with complex underlying data using visualisations such as charts, tables, maps, or even text typically on a single display. By bringing the most important information in a single place, dashboards enable performance monitoring and support decision making. Although nowadays dashboards are widely adopted in many domains, they involve challenges that prevent users from utilising them as they were intended. For example, having a dashboard with too much data can negatively affect decision making and lead to misleading interpretation. Through this research, we identify and investigate the challenges associated with dashboards, what users do in response to those challenges, and what adaptations can be applied to mitigate these challenges. Consequently, we aim to examine and evaluate a set of adaptation techniques that can improve the experience of users interacting with dashboards.
BACKGROUND:
The prognosis of idiopathic pulmonary fibrosis (IPF) can be predicted by the gender, age, and physiology (GAP) index. However, antifibrotic therapy (i.e., nintedanib and pirfenidone) may improve survival.
AIMS:
This study aimed to compare the outcomes of antifibrotic-treated IPF with the survival predicted by the GAP index.
METHODS:
A retrospective cohort study was conducted from March 2014 to January 2020. The electronic health-care records of all IPF patients treated with nintedanib or pirfenidone were reviewed. Besides standard demographic and mortality data, the variables required to calculate the GAP index were also extracted.
RESULTS:
Eighty-one patients (male 55, 68%; age 71.4 ± 10.2 years) with IPF received antifibrotic therapy (nintedanib 44.4%; pirfenidone 55.6%; mean follow-up 35 ± 16.5 months). Cumulative mortality (whole cohort 3 years 12%; 4 years 26%; 5 years 33%) was significantly less than predicted by the GAP index.
CONCLUSIONS:
The survival of antifibrotic-treated IPF is better than predicted by the GAP index. Novel systems for prognostication are required. The survival benefit from pirfenidone and nintedanib seem similar overall.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.